All In Biotech

BLA 761432 · Merck Sharp Dohme

Enflonsia

Clesrovimab-Cfor · Solution · Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody

NovelPriority review

CDER novel approval, Jun 9, 2025: To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jun 9, 2025

Approved uses

2

Original approval plus efficacy supplements

Registered trials

5

2 Phase 3, 0 recruiting

FAERS reports

13

2 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 14, 2026.

ENFLONSIA ™ is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. ENFLONSIA is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. ( 1 )

Mechanism: ENFLONSIA is a monoclonal antibody with anti-RSV activity [see Clinical Pharmacology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 14, 2026 Supplement 3 · Efficacy LetterLabel
  • Jun 9, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
  • ENFLONSIA · CLESROVIMAB-CFOR 105MG/0.7ML · INJECTION, SOLUTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clesrovimab" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event5
  • extra dose administered2
  • injection site pain2
  • injection site swelling2
  • product administered to patient of inappropriate age2
  • pyrexia2
  • respiratory syncytial virus infection2
  • bacterial test positive1
  • blood culture positive1
  • influenza1
  • injection site mass1
  • medication error1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20256
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.